Urban-Gro: Is this Cannabis Stock a Strong Buy?
With a 2021 IPO sending the stock soaring to 400%, Urban-Gro should definitely be on the minds of every cannabis stock investor. But is Urban-Gro cannabis stock a strong buy? Urban-Gro (Nasdaq: UGRO) supports cultivation facilities by performing design, architectural,...
22nd Century: Is this Cannabis Stock a Buy and Hold?
22nd Century Group (Nasdaq: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene editing, and modern plant...
Why is VFF a strong buy?
After rebalancing our portfolios this week, we’ve got exciting news about several new opportunities. We are particularly excited about Village Farms International (VFF). Keep reading to see why VFF is a strong buy. As you know, Cannin’s Cannabis Stock...
With Colombia on the Rise is PharmaCielo Stock a Buy?
In an increasingly globalized cannabis market, Colombia continues to make headlines. In fact, this July, Colombian President Ivan Duque gave the Colombian cannabis industry a huge bump by signing a directive to allow for the export of dried cannabis flower. Several...
Should You Add HempAmericana Stock to Your Watchlist?
As you may know, the analysts at Cannin are constantly evaluating the next best hemp stock investment opportunities. With HempAmericana, Inc. (HMPQ) gaining 10% on the week, we wanted to cover this hemp stock for our audience. But should you add HempAmericana stock to...
CanninPlus with Trading Alerts!
Get advance notice of profitable cannabis & hemp stock trades. Use our machine learning algorithm to start profiting from this explosive industry.
$99 / month after 7-day trial.
Still unsure? Schedule demo at demo@cannin.com
or call 720-254-1374
The Best Cannabis Stocks for 2021
-
Cannin Report Q2 2021
$49.00
-
Cannin Report Q1 2021
$29.00
-
The Cannin Report 2020
$19.00
-
FREE Sample Cannin Report Q1 2020 - Our #1 Stock Pick
$0.00
-
The Cannin Report Q4 2019
$29.00
